Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company — a sign of big pharmaceutical companies’ growing interest in stem cells (…)
The relatively small payment reflects that “it’s really early for cell therapy and there’s more research to be done,” said Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, a unit created by the company about 18 months ago to develop treatments based on stem cells (…)
Image by Ed Yourdon via Flickr
The coordinator of the health commission of the Federal-Regional government conference, Enrico Rossi, spoke about the statements made by Undersecretary for Healthcare Ferruccio Fazio on the stem cell ban.
“In the Federal-Regional conference, which met on February 26,” said Rossi, Healthcare Councilman of Tuscany, “the agreement on the Employment, Healthcare, and Social Policy Minister’s proposal between the federal government, the regions, and the autonomous provinces of Trento and Bolzano for 2008 regarding stem cell research, was ratified unanimously, and in that meeting, there were no requests to modify the text in a technical meeting between
All over the world there are desperate patients looking for institutions that promise to heal them with stem cells. But the treatments that are promised must be controlled and regulated, said two scholars in Science magazine. Today, recognized treatments with stem cells involve blood diseases or immune system defects, wrote the Thai researcher Sorapop Kiatpongsan and his Japanese colleague Douglas Sipp. In reality, many other treatments have been offered without proof of their effectiveness.
For example, treatments are being offered to cure heart disease, autism, Down’s syndrome, and epilepsy. These treatments are ineffective and are mainly
South Korea’s government drug agency cleared the way Thursday for commercial sales of what it called the world’s first approved medicine using stem cells collected from other people.
Cartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns’ umbilical cord blood, the Korea Food and Drug Administration said.
“Cartistem is… the world’s first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis,” the administration said in a statement.
Medipost said 27 billion won ($23.8 million) from private investors and government
Stem Cell researchers at Cambridge and Edinburgh have discovered a promising stem cell therapy for multiple sclerosis. While much work is still needed to translate the discovery into an effective treatment, this breakthrough provides a promising road map towards a cure.
A video story featuring the SCI’s Robin Franklin can be viewed on the BBC News website.